Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DXCM NASDAQ:PODD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$68.20-1.9%$79.26$57.52▼$93.25$27.26B1.485.75 million shs6.15 million shsPODDInsulet$327.80-2.2%$316.76$225.37▼$353.50$23.59B1.36589,382 shs435,712 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-1.88%-10.91%-17.09%-19.46%-2.15%PODDInsulet-2.18%-1.30%-0.90%+7.04%+37.17%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDXCMDexCom$68.20-1.9%$79.26$57.52▼$93.25$27.26B1.485.75 million shs6.15 million shsPODDInsulet$327.80-2.2%$316.76$225.37▼$353.50$23.59B1.36589,382 shs435,712 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDXCMDexCom-1.88%-10.91%-17.09%-19.46%-2.15%PODDInsulet-2.18%-1.30%-0.90%+7.04%+37.17%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDXCMDexCom 2.91Moderate Buy$99.8946.47% UpsidePODDInsulet 2.89Moderate Buy$343.064.65% UpsideCurrent Analyst Ratings BreakdownLatest PODD and DXCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/16/2025PODDInsuletPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$320.00 ➝ $360.009/12/2025PODDInsuletJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$340.00 ➝ $415.009/8/2025DXCMDexComOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform9/8/2025PODDInsuletOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$324.00 ➝ $365.008/21/2025DXCMDexComArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$100.008/21/2025PODDInsuletBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$266.00 ➝ $300.008/8/2025PODDInsuletCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$331.00 ➝ $353.008/8/2025PODDInsuletRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$330.00 ➝ $350.008/8/2025PODDInsuletWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$330.00 ➝ $350.008/7/2025PODDInsuletMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight8/7/2025PODDInsuletJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDXCMDexCom$4.30B6.22$2.20 per share30.93$5.38 per share12.68PODDInsulet$2.07B11.14$4.34 per share75.54$17.27 per share18.98Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDXCMDexCom$576.20M$1.4447.3627.721.4613.29%30.41%10.08%10/23/2025 (Estimated)PODDInsulet$418.30M$3.2999.6465.962.7810.01%23.78%9.30%11/6/2025 (Estimated)Latest PODD and DXCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PODDInsulet$0.92$1.17+$0.25$0.32$612.31 million$649.10 million7/30/2025Q2 2025DXCMDexCom$0.45$0.48+$0.03$0.45$1.13 billion$1.16 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDXCMDexComN/AN/AN/AN/AN/APODDInsuletN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDXCMDexCom0.481.521.35PODDInsulet0.642.261.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDXCMDexCom97.75%PODDInsuletN/AInsider OwnershipCompanyInsider OwnershipDXCMDexCom0.32%PODDInsulet0.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDXCMDexCom10,300392.16 million390.90 millionOptionablePODDInsulet3,90070.39 million70.12 millionOptionablePODD and DXCM HeadlinesRecent News About These CompaniesInsulet Corporation $PODD Shares Sold by Assenagon Asset Management S.A.September 23 at 3:47 AM | marketbeat.comToth Financial Advisory Corp Increases Stock Holdings in Insulet Corporation $PODDSeptember 22 at 5:00 AM | marketbeat.comInsulet Corporation $PODD Shares Acquired by IFM Investors Pty LtdSeptember 22 at 3:58 AM | marketbeat.comSwedbank AB Has $22.77 Million Stock Position in Insulet Corporation $PODDSeptember 21 at 3:53 AM | marketbeat.comSenator Tina Smith has filed a new financial disclosure - here’s what we seeSeptember 20, 2025 | quiverquant.comQInsulet Corporation (NASDAQ:PODD) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 20, 2025 | marketbeat.comMn Services Vermogensbeheer B.V. Purchases 1,900 Shares of Insulet Corporation $PODDSeptember 20, 2025 | marketbeat.comCiti Reaffirms Their Buy Rating on Insulet (PODD)September 19, 2025 | theglobeandmail.comMarshall Financial Group LLC Takes Position in Insulet Corporation $PODDSeptember 19, 2025 | marketbeat.comInsulet (PODD) Gets a Buy from Piper SandlerSeptember 19, 2025 | theglobeandmail.comTruist Financial Sticks to Its Buy Rating for Insulet (PODD)September 19, 2025 | theglobeandmail.comAlecta Tjanstepension Omsesidigt Boosts Position in Insulet Corporation $PODDSeptember 19, 2025 | marketbeat.comAaron Wealth Advisors LLC Takes $291,000 Position in Insulet Corporation $PODDSeptember 19, 2025 | marketbeat.comInsulet Corporation $PODD Position Increased by Czech National BankSeptember 19, 2025 | marketbeat.comStrs Ohio Makes New $1 Million Investment in Insulet Corporation $PODDSeptember 19, 2025 | marketbeat.comInsulet (NASDAQ:PODD) Price Target Raised to $360.00September 19, 2025 | americanbankingnews.comInsulet (NASDAQ:PODD) Trading Down 4.2% - What's Next?September 18, 2025 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) StockSeptember 18, 2025 | marketbeat.comInsulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New PaletteSeptember 18, 2025 | bakersfield.comBInsulet Corporation (PODD) Benefited from Omnipod SalesSeptember 18, 2025 | insidermonkey.comInsulet Corporation (PODD) Benefited from Omnipod SalesSeptember 18, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Take Profits Now: 3 Overbought Stocks Primed for a PullbackBy Dan Schmidt | August 25, 2025What NVIDIA’s Big Bet on Rival Quantinuum Means for D-Wave StockBy Nathan Reiff | September 8, 2025Best Bang For Your Buck? 2 Bargain Stocks with 30%+ UpsideBy Nathan Reiff | September 14, 2025PODD and DXCM Company DescriptionsDexCom NASDAQ:DXCM$68.20 -1.31 (-1.88%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$68.24 +0.04 (+0.06%) As of 09/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.Insulet NASDAQ:PODD$327.80 -7.32 (-2.18%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$327.92 +0.12 (+0.04%) As of 09/23/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Mega-Cap Giants Just Increased Dividends by 7% or More 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Amprius Technologies: Anatomy of a Textbook, Raging Bull Market Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
